{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-041514","form_type":"8-K","ticker":"VNDA","cik":"0001347178","company_name":"Vanda Pharmaceuticals Inc.","filed_at":"2024-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.885751+00:00","generated_at":"2026-06-05T21:50:40.319715+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Vanda approves 2023 bonuses, 2024 salaries, and RSU grants for NEOs","bullets":["CEO Polymeropoulos receives $983K bonus for 2023, 450,000 RSUs vesting over 4 years.","2024 base salaries: CEO $933K, CFO Moran $541K, others $541-560K.","2024 target bonuses: 80% CEO, 45% for other NEOs.","RSU grants total 857,700 shares across five executives.","Compensation committee reviewed Willis Towers Watson peer group analysis."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-041514","json":"https://secwatch.observer/filing/0001193125-24-041514.json","markdown":"https://secwatch.observer/filing/0001193125-24-041514.md","text":"https://secwatch.observer/filing/0001193125-24-041514.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347178/000119312524041514/0001193125-24-041514-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347178/000119312524041514/d796267d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T21:50:40.319715+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}